The FDA last week approved Johnson & Johnson’s Invega Hafyera, a long-acting atypical antipsychotic, for the treatment of schizophrenia, expanding the drugmaker’s hold on the market. The drug is the first-ever twice-yearly injectable approved to treat the disease. First approved in 2006, J&J’s extended release Invega tablet currently holds covered or better status for 75% of all insured lives under the pharmacy benefit. Two other long-acting injectable forms of the drug, Invega Sustenna (77% covered or better) and Invega Trinza (58% covered or better) are also on the market.

SOURCE: MMIT Analytics, as of 9/1/21